CClinicalTrials.gg
RecruitingNCT06408207Updated Feb 6, 2026

CGM Academy for Youth With Type 1 Diabetes

An interventional study of CGM Academy in Type1 Diabetes, sponsored by Children's Hospital Los Angeles. Recruiting at 1 site in United States. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Children's Hospital Los Angeles · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
8 Years to 18 Years
Sex
All
01

Study summary

The goal of this randomized clinical trial is to compare the effects of a virtual education curriculum in blood glucose variation of youth with type 1 diabetes wearing continuous glucose monitoring (CGM) device. The main questions the study aims to answer are:

  • Do participants undertaking the proposed curriculum present improved glucose variation than participants of standard education?
  • Explore relationships between participant's glycemic outcomes with diabetes distress, diabetes family responsibilities, and number of hours of diabetes education.

Participants in the intervention group will:

  • receive an interactive workbook with problem-based learning scenarios and video links about CGM and glucose management strategies.
  • participate in four in-depth online group sessions with diabetes care and education specialists
  • complete questionnaires three times: at the time of study enrollment, week 4 and 6 months.

Participants in the comparison group will:

  • receive standard education provided to all patients at CHLA
  • complete questionnaires three times: at the time of study enrollment, week 4 and 6 months.
Read the detailed description

Youth with type 1 diabetes (T1D) are at increased risk for kidney failure, vision loss, heart disease, and premature mortality due to challenges with glycemic excursions. Continuous glucose monitoring (CGM) systems represent an important advance in diabetes technology with significant advantages over self-monitored blood glucose and the potential to optimize glycemic management. Despite these advances, youth with T1D, including patients at Children's Hospital Los Angeles (CHLA), fail to achieve recommended glycemic targets, highlighting the opportunity for testing innovative diabetes education programs aimed at increased technology uptake such as the CGM Academy intervention.

02

Conditions studied

  • Type1 Diabetes

Keywords

  • Continuous Glucose Monitoring
  • Glycemic Control
  • Diabetes Education
  • Type1 Diabetes
03

In context

Lead sponsor

Children's Hospital Los Angeles is the lead sponsor of 150 studies on the registry; 46 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Current age of 8-18 years, age group eligible for CGM therapy with Dexcom G6 and G7
  • T1D duration ≥6 months, as insulin adjustments during honeymoon stage differs from establishedT1D
  • Able to speak, read, and write English or Spanish
  • Smartphone compatible with Dexcom G6 and G7application
  • Ability to participate in virtual visits

Exclusion criteria

Exclusion Criteria:

  • Known history of medical adhesive allergies
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    CGM Academy

    * receive an interactive workbook with problem-based learning scenarios and video links about CGM and glucose management strategies. * participate in four in-depth online group sessions with diabetes care and education specialists * complete questionnaires three times: at the time of study enrollment, week 4 and 6 months.

    Behavioral: CGM Academy

  • No intervention
    Standard Diabetes Education

    * receive standard education provided to all patients at CHLA * complete questionnaires three times: at the time of study enrollment, week 4 and 6 months.

Interventions

  • BehavioralCGM Academy

    Educational materials as well as online sessions with diabetes educators.

06

What researchers measure

Primary outcomes

  1. Mean change in Hemoglobin A1c from baseline to 6 months

    Change in Hemoglobin A1c

    Time frame: Baseline to 6 months

Secondary outcomes

  1. Mean change in HbA1c (%) from baseline to 6 months.

    Change in Hemoglobin A1c

    Time frame: Baseline to 6 months

  2. Mean change in CGM metrics measured by CGM readings

    % Glucose Time in Range (70-180 mg/dL), % Glucose Time Below Range (\<70mg/dL), % Glucose Time Above Range (\>180mg/dL).

    Time frame: Week 4 & 6 months

  3. Change in perceived diabetes distress at baseline, week 4 & 6 months

    The Problem Areas in Diabetes survey (PAID) is an 18-item survey to assess the perceived burden associated with diabetes. Youth and caregivers are given statements about diabetes-related issues and report on a 5-point Likert scale (0 = not a problem, 1 = minor problem, 2 = moderate problem, 3 = somewhat serious problem, 4 = serious problem) the degree to which the statements are a problem for them. Increasing scores denote increased burden perceived.

    Time frame: Baseline, Week 4 & 6 months

  4. Change in perceived diabetes family responsibility at baseline, week 4 & 6 months.

    The Diabetes Family Responsibility Questionnaire (DFRQ) is a 14-item validated survey assessing parental and child involvement in various diabetes management tasks. Youth and caregivers report on a 3-point scale (1=child, 2=equal, 3=parent) who is responsible for a given diabetes task. Higher scores indicate more parental involvement in diabetes management.

    Time frame: Baseline, week 4 & 6 months

  5. Average number of diabetes educator hours used per study participant at week 4 & 6 months.

    Number of hours spent in diabetes education

    Time frame: Week 4 and 6 months

  6. Perceived benefits of Continuous Glucose Monitor (CGM) use

    Adolescent Benefits and Burdens of CGM Survey - BenCGM \& BurCGM. Participants answer each question on a scale of Strong Disagree, Disagree, Neutral, Agree, Strongly Agree.

    Time frame: week 4 & 6 months

  7. Perceived burden of Continuous Glucose Monitor (CGM) use

    Adolescent Benefits and Burdens of CGM Survey - BenCGM \& BurCGM. Participants answer each question on a scale of Strong Disagree, Disagree, Neutral, Agree, Strongly Agree.

    Time frame: week 4 & 6 months

07

Study locations

1 of 1 sites recruiting
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06408207
Lead sponsor
Children's Hospital Los Angeles
Responsible party
Barber, Rebecca (Principal Investigator, Children's Hospital Los Angeles) — Principal investigator
First posted
May 10, 2024
Start date
May 1, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Feb 6, 2026

Study contacts

Rebecca Barber, PhD, RN
Contact
rbarber@chla.usc.edu
(323) 361-1359 ext. 11359
Natalia Garban
Contact
ngarban@chla.usc.edu
Rebecca Barber, PhD, RN
principal investigator · Children's Hospital Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion